|Dr. Michael E. Castagna Pharm.D.||CEO & Director||1.12M||N/A||1977|
|Mr. Steven B. Binder||Chief Financial Officer||772.05k||N/A||1963|
|Mr. Joseph Kocinsky M.B.A., M.S.||Chief Technology Officer||608.75k||N/A||1964|
|Dr. David B. Thomson||Exec. VP, Gen. Counsel & Sec.||772.9k||N/A||1967|
|Dr. Stuart A. Tross Ph.D.||Chief People & Workplace Officer||652.85k||N/A||1967|
|Mr. Thomas Hofmann M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Rosabel Realica Alinaya||VP of Investor Relations & Treasury||N/A||N/A||1961|
|Mr. John F. Bedard||Sr. VP of Worldwide Regulatory Affairs||N/A||N/A||1950|
|Mr. James Patrick McCauley Jr., J.D., M.B.A.||Chief Commercial Officer||N/A||N/A||1966|
|Mr. Alejandro Galindo M.B.A., M.S.||Exec. VP of Endocrine Bus. Unit||N/A||N/A||1972|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MannKind Corporation’s ISS governance QualityScore as of 1 June 2022 is 4. The pillar scores are Audit: 5; Board: 4; Shareholder rights: 4; Compensation: 3.